

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents,
Washington, D.C. 20231.

on

Feb. 28, 1996

TOWNSEND and TOWNSEND and CREW

By Katie M. Murphy

18C3

PATENT

FAX CENTER

RECEIVED

Attorney Docket No. 16270-002120US

FEB 28 1996

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PETER A. SEUBERT et al.

Application No.: 08/466,554

Filed: June 6, 1995

For: METHODS FOR AIDING IN THE
DIAGNOSIS OF ALZHEIMER'S
DISEASE BY MEASURING
AMYLOID- β PEPTIDE (x- \geq 41)
AND TAU

Examiner: P. Duffy

Art Unit: 1802

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER
37 CFR §1.97 and §1.98**BEST AVAILABLE COPY**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 is being called to the attention of the Examiner. In accordance with 37 C.F.R. 1.98(d), copies of each can be found in parent application serial no. 08/339,141 filed 11/14/94.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the

PETER A. SEUBERT et al.
Application No.: 08/466,554
Page 2

PATENT

Commissioner is authorized to charge such fee to Deposit Account No. 20-1430. Please charge any additional fees or credit any overpayment to the above-noted Deposit Account.

Respectfully submitted,



John R. Storella
Reg. No. 32,944

TOWNSEND and TOWNSEND and CREW
One Market Plaza
Steuart Street Tower, 20th Floor
San Francisco, California 94105

(415) 326-2400
Fax (415) 326-2422

JRS:kz

BEST AVAILABLE COPY

FORM PTO-1449 (Modified)		Attorney Docket No. 15270-002120US	Serial No.: 08/466,554			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: PETER A. SEUBERT et al.				
		Filing Date: June 6, 1995	Group: unassigned			
Reference Designation		U.S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AA	5,262,332	11/16/93	Selkoe	436	518	
AB	5,234,814	08/10/93	Card et al.	435	7.21	
AC	5,223,482	06/29/93	Schilling, Jr., et al.	514	12	
AD	5,220,013	06/15/93	Ponte et al.	536	23.5	
AF	5,213,962	05/25/93	Van Nostrand et al.	435	7.1	
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
AG	WO 94/17197	08/04/94	PCT	C12P	21/08	no
AH	WO 90/12871	11/01/90	PCT	C12N	5/20	yes
AI	62-267297	11/19/87	JP	C07K	15/04	yes
AJ	04-252954	09/08/92	JP	G01N	33/53	abstract only
AK	04-252956	09/08/92	JP	G01N	33/53	abstract only
AL	04-252955	09/08/92	JP	G01N	33/53	abstract only
AM	0 274 826	07/20/88	EP	C12N	15/00	yes
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
AO	H. Hamazaki (1995) <i>Biochem. Biophys. Res. Comm.</i> 211(2):349-353. Amyloid P Component Promotes Aggregation Of Alzheimer's β -Amyloid Peptide					
AP	R. Motter et al. (1995) <i>Annals of Neurology</i> 38(4):643-648 Reduction of β -Amyloid Peptides in the Cerebrospinal Fluid of Patients with Alzheimer's Disease					
AQ	L. Chang et al. (1994) <i>Neurology</i> v. 44 (4 Sup. 2) β -Amyloid Protein in Cerebrospinal Fluid of Alzheimer Disease: Correlations with MMSE					
AR	L. Higgins et al. (1994) <i>Annals of Neurology</i> 35(5):598-607 Transgenic Mouse Brain Histopathology Resembles Early Alzheimer's Disease					
AS	G. Murphy (1994) <i>American J. of Pathology</i> 144(5):1082-1088 Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders					
AT	T. Pirttila (1994) <i>J. Neurological Sciences</i> 127:90-95. Soluble amyloid β -protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls					
AU	W. Van Nostrand et al. (1992) <i>Proc. Natl. Acad. Sci USA</i> 89:2551-2555 Decreased levels of soluble amyloid β -protein precursor in cerebrospinal fluid of live Alzheimer's disease patients					
AV	M. Tabaton et al. (1994) <i>Biochem. Biophys. Res. Comm.</i> 200(3):1598-1603 Soluble Amyloid β -Protein Is A Marker Of Alzheimer Amyloid In Brain But Not In Cerebrospinal Fluid					
EXAMINER	DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		Attorney Docket No. 15270-002120US	Serial No.: 08/466,554			
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: PETER A. SEUBERT et al.				
		Filing Date: June 6, 1995	Group: unassigned			
Reference Designation		U.S. PATENT DOCUMENTS				
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
AW						
AX						
AY						
AZ						
BA						
BB						
BC						
BD						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (yes/no)
BE						
BP						
BG						
RH						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
BI	C. Vigo-Pelfrey et al. (1994) <i>Society for Neuroscience Abstracts</i> vol. 20 #191.2 Detection of $\text{A}\beta_{1-42}$ In CSF And Various Cell Conditioned Media					
BJ	K. Urakami et al. (1992) <i>Acta Neurol Scand</i> 85:343-346. Amyloid β protein precursors with kunitz-type inhibitor domains and acetyl-cholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type					
BK	R. Prior et al. (1991) <i>Neuroscience Letters</i> 124:69-73. Quantitative changes in the amyloid β A4 precursor protein in Alzheimer cerebrospinal fluid					
BL	B. McDonald et al. (1988) <i>Alzheimer Disease and Associated Disorders</i> 2(3):186. The Characterisation And Purification Of A Protein Present In Cerebrospinal Fluid And Serum, Using A Monoclonal Antibody Which Reacts Immunohistochemically With Amyloid Deposits In Alzheimer Brains					
BM	D. Allsop (1986) <i>Neuroscience Letters</i> 68:252-256. Monoclonal Antibodies Raised Against A Subsequence Of Semile Plaque Core Protein React With Plaque Cores, Plaque Periphery And Cerebrovascular Amyloid In Alzheimer's Disease					
BN	T. Ishii (1986) <i>Neuropathology and Applied Neurobiology</i> 12:441-445. A Monoclonal Antibody To Amyloid In The Brains Of Patients With Alzheimer's Disease					
BO						
EXAMINER	DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.